EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing novel topical non-antibiotic antimicrobial products for the global eye care market, announces that President and CEO Ron Najafi, Ph.D., will present at the Rodman & Renshaw 17th Annual Global Investment Conference on Thursday, September 10, 2015 at 3:25 p.m. Eastern time (12:25 p.m. Pacific time). The conference is being held at the St. Regis Hotel
ALAMEDA, Calif.–(BUSINESS WIRE)–InSite Vision Announces New Date for Special Stockholder Meeting
BARCELONE, Espagne–(BUSINESS WIRE)–À l’occasion de l’Ophthalmology Futures European Forum 2015, Salutaris Medical Devices (SalutarisMD®) a annoncé que sa source de curiethérapie à radionucléides (SCR) SMD Sr90-1 a obtenu l’homologation 510(k) de l’Agence américaine des produits alimentaires et des médicaments (la « FDA »). La SCR SMD Sr90-1 est indiquée pour la curiethérapie épisclérale des tumeurs et des croissances bénignes, elle est prévue pour une utilisation dans un système applicateur d
BARCELONA, Spanien–(BUSINESS WIRE)–Salutaris Medical Devices (SalutarisMD®) gab auf dem Ophthalmology Futures European Forum 2015 bekannt, dass seine SMD Sr90-1-Radionuklid-Brachytherapie-Strahlenquelle (RBS) die Zulassung der US-Gesundheitsbehörde nach dem 510(k)-Verfahren erhalten hat. Die SMD Sr90-1 RBS ist bei der episkleralen Brachytherapie von Tumoren und gutartigen Wucherungen angezeigt und für die Verwendung in einem manuellen Brachytherapie-Applikator-System bestimmt. Dr. Laurence Ma
BARCELLONA, Spagna–(BUSINESS WIRE)–Nel corso dell’Ophthalmology Futures European Forum 2015, Salutaris Medical Devices (SalutarisMD®) ha annunciato che il suo prodotto SMD Sr90-1 Radionuclide Brachytherapy Source (RBS) ha ricevuto l’approvazione 510(k) dalla Food and Drug Administration (FDA) degli Stati Uniti. SMD Sr90-1 RBS è indicato per la brachiterapia episclerale dei tumori e delle escrescenze benigne e va utilizzato nell’ambito di un sistema con applicatore manuale per brachiterapia. “
BARCELONA, Spain–(BUSINESS WIRE)–At Ophthalmology Futures European Forum, Salutaris Medical Devices announces 510(k) clearance for device indicated for episcleral brachytherapy.
DUBLIN, Calif.–(BUSINESS WIRE)–ZEISS sets the pace in OCT innovation with the FDA 510(k) clearance of AngioPlex OCT Angiography, the first next generation vascular imaging technology approved in the U.S.
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that it has been awarded a Small Business Innovation Research (SBIR) grant from the National Eye Institute (NEI), part of the National Institutes of Health (NIH), to fund Investigational New Drug (IND)-enabling preclinical development of Ocata’s proprietary photoreceptor progenitor product for the treatment of retinal degenerative diseases, such as r
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Eleven announces promotions of Gary Sternberg, MD, MBA, to Chief Business Officer and John McCabe, CPA, to SVP, Finance. Mr. McCabe is also Principal Financial and Accounting Officer.
WASHINGTON–(BUSINESS WIRE)–Optica, The Optical Society’s newest journal, dedicated to rapidly disseminating the highest impact peer-reviewed research across the entire spectrum of optics and photonics, has celebrated its one-year anniversary. In its first year, Optica has established itself as a trusted source for some of the best and most exciting work in the optics and photonics field, demonstrated by 45% growth in article downloads in 2015 so far and 1 in 6 articles being featured in mains
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Abbie Celniker, CEO of Eleven Biotherapeutics, will present at the NewsMakers in the Biotech Industry Conference ion Thursday, September 10, 2015 at 3:30 pm ET.
ALAMEDA, Calif.–(BUSINESS WIRE)–InSite Vision Inc. (OTCBB: INSV) today announced that InSite and QLT Inc. (NASDAQ: QLTI) (TSX: QLT) entered into a revised merger agreement under which QLT will acquire InSite Vision. Under the terms of the revised mer…
WASHINGTON–(BUSINESS WIRE)–To promote the progress and promise of light research and education, leading U.S. science organizations will host two events on Saturday, September 12, 2015, in Washington. The events are organized by the National Science Foundation (NSF) in conjunction with The American Institute of Physics, The American Physical Society, The IEEE Photonics Society, The National Academy of Sciences, The Optical Society and the International Society for Optics and Photonics (SPIE).
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (TOKYO: 4589) (“Acucela” or the “Company”), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, announced today that it has hired Dr. George Lasezkay as Executive Vice President, Legal Affairs, effective Aug. 24. Dr. Lasezkay will head up Acucela’s legal team and be the primary legal advisor to CEO Ryo Kubota and t
BARCELONA, Spain–(BUSINESS WIRE)–Glaukos Technologies Featured in Nine Podium and Poster Presentations at 2015 ESCRS
CARLSBAD, Calif.–(BUSINESS WIRE)–Heidelberg Engineering has entered into a patent license agreement with Massachusetts General Hospital (MGH) in Boston. The agreement grants global and exclusive rights to 77 basic patents and patent applications whic…
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay Pharmaceuticals’ intelli-Case featured on ABC7 in San Francisco Bay Area.
PLEASANTON, Calif.–(BUSINESS WIRE)–The revolutionary RapidHIT® System from IntegenX delivered a stunning arrest in the UK last week. A suspect was arrested for a minor crime and swabbed for a DNA reference sample while in custody. His DNA profile was generated in less than two hours using the RapidHIT System at UK forensic laboratory, Key Forensic Services. Upon upload to the UK’s National DNA Database® (NDNAD), the suspect’s profile immediately matched with a DNA profile recovered from a ser
ALAMEDA, Calif.–(BUSINESS WIRE)–InSite Vision Inc. (OTCBB:INSV) today announced that InSite’s Board of Directors determined that the previously announced unsolicited offer from a multi-national pharmaceutical company (the “Bidder”) to acquire InSite for $0.25 per share in an all-cash transaction constitutes a “Company Superior Proposal” as defined in InSite’s previously announced definitive agreement with QLT Inc. dated as of June 8, 2015, as amended (NASDAQ: QLTI) (TSX: QLT). Under the terms